MANNARELLI, CARMELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.881
EU - Europa 2.989
AS - Asia 1.672
SA - Sud America 154
AF - Africa 41
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 3
Totale 8.754
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.840
RU - Federazione Russa 896
IT - Italia 645
PL - Polonia 630
SG - Singapore 487
CN - Cina 446
HK - Hong Kong 238
IE - Irlanda 165
VN - Vietnam 160
KR - Corea 129
BR - Brasile 124
SE - Svezia 123
DE - Germania 121
FR - Francia 98
FI - Finlandia 88
GB - Regno Unito 68
IN - India 58
CH - Svizzera 56
JO - Giordania 36
NL - Olanda 29
CA - Canada 26
ES - Italia 19
ID - Indonesia 19
JP - Giappone 18
TW - Taiwan 18
AU - Australia 14
IQ - Iraq 14
BE - Belgio 10
CI - Costa d'Avorio 8
MX - Messico 8
CZ - Repubblica Ceca 7
NG - Nigeria 7
NP - Nepal 7
AR - Argentina 6
AT - Austria 6
BD - Bangladesh 6
EC - Ecuador 6
RO - Romania 6
ZA - Sudafrica 6
AE - Emirati Arabi Uniti 5
PH - Filippine 5
PK - Pakistan 5
SA - Arabia Saudita 5
CL - Cile 4
EG - Egitto 4
KE - Kenya 4
TR - Turchia 4
UA - Ucraina 4
VE - Venezuela 4
AL - Albania 3
LT - Lituania 3
MY - Malesia 3
PY - Paraguay 3
UY - Uruguay 3
BH - Bahrain 2
CO - Colombia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
HU - Ungheria 2
JM - Giamaica 2
KZ - Kazakistan 2
LV - Lettonia 2
MU - Mauritius 2
NO - Norvegia 2
TN - Tunisia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AZ - Azerbaigian 1
BJ - Benin 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BT - Bhutan 1
BW - Botswana 1
BY - Bielorussia 1
CR - Costa Rica 1
DK - Danimarca 1
ET - Etiopia 1
EU - Europa 1
GR - Grecia 1
KH - Cambogia 1
LB - Libano 1
LU - Lussemburgo 1
MA - Marocco 1
MT - Malta 1
PA - Panama 1
PE - Perù 1
SI - Slovenia 1
SN - Senegal 1
SV - El Salvador 1
YT - Mayotte 1
Totale 8.754
Salva come PNG Salva come JPEG
Città #
Santa Clara 840
Warsaw 627
Ashburn 509
Singapore 333
Fairfield 332
Chandler 197
Hong Kong 195
Dublin 165
Woodbridge 165
Seattle 150
San Jose 135
Seoul 126
Houston 123
Beijing 121
Wilmington 118
Cambridge 108
Florence 101
Ann Arbor 94
Milan 68
Hefei 61
Altamura 60
Bern 55
Buffalo 55
Lawrence 55
Munich 55
Los Angeles 53
Ho Chi Minh City 48
Princeton 48
Dallas 47
Lauterbourg 42
Rome 39
Hanoi 37
Mumbai 36
Helsinki 34
Boston 33
The Dalles 32
New York 31
Turku 29
Bremen 27
Council Bluffs 26
Shanghai 26
Kent 23
Paris 23
London 22
Clifton 20
Moscow 19
San Diego 19
Boardman 17
Tokyo 16
Frankfurt am Main 15
Melbourne 14
Taipei 14
Jakarta 13
Dong Ket 12
Redondo Beach 12
Medford 11
São Paulo 11
Brussels 10
Orem 10
Toronto 10
Da Nang 9
Ealing 9
Figino 9
Palermo 9
Tianjin 9
Abidjan 8
Baghdad 8
Barcelona 8
Brooklyn 8
Phoenix 8
Brescia 7
Düsseldorf 7
Falls Church 7
Fiesole 7
Guangzhou 7
Modena 7
Prague 7
Abuja 6
Amsterdam 6
Charlotte 6
Chicago 6
Dearborn 6
Elk Grove Village 6
Miano 6
Naples 6
Norwalk 6
Pian di Scò 6
Pune 6
Turin 6
Verona 6
Vienna 6
Cagliari 5
Chennai 5
Genoa 5
Haiphong 5
Hillsboro 5
Jacksonville 5
Johannesburg 5
Montreal 5
Austin 4
Totale 5.989
Salva come PNG Salva come JPEG
Nome #
A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells 353
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms 330
“MiRNA expression in Primary Myelofibrosis: characterization and pathophysiology implications” 311
Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells 270
Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants 259
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis 246
Spectrum of ASXL1 mutations in primary myelofibrosis: Prognostic impact of the ASXL1 p.G646Wfs∗12 mutation 229
Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation 225
Targeted deep sequencing in polycythemia vera and essential thrombocythemia 225
Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) 224
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis 219
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: Pathogenetic insight and diagnostic value 216
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms 215
Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib 210
Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in Primary Myelofibrosis 208
Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms 199
Mutations and prognosis in primary myelofibrosis. 198
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. 197
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea 196
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 195
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis 190
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis 190
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients 188
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera 185
Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group 183
Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients 181
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis 178
Screening for Hereditary Alpha-Tryptasemia in Subjects with Systemic Mastocytosis (SM) and Non-SM Mast Cell Activation Symptoms 176
Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis 174
RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features 171
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. 170
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. 169
Novel insights into myelofibrosis pathophysiology and treatment 165
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. 165
Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2V617F Variant Allele Frequency≤ 1% 158
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. 158
miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells unveils the role of miR-155/JARID2 axis in abnormal megakaryopoiesis. 158
Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis 158
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients 157
JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease 151
Diagnostic and therapeutic challenges in mast cell sarcoma 149
Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations. 147
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial 147
The ERCC2 Gln/Gln polymorphism at codon 751 is not associated with leukaemic transformation in primary myelofibrosis. 144
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates 133
Totale 8.870
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.883
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.883
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022315 4 17 36 8 16 19 9 41 11 16 52 86
2022/2023959 67 177 57 72 66 135 106 60 95 18 32 74
2023/2024471 25 35 61 22 51 55 18 113 11 21 38 21
2024/20252.560 72 249 161 426 670 386 48 106 115 86 116 125
2025/20262.469 335 297 199 162 317 94 316 99 152 166 66 266
2026/20277 7 0 0 0 0 0 0 0 0 0 0 0
Totale 8.870